Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISP-10 in Advanced Gastrointestinal Cancers
NCT07544589Phase 1Recruiting
- Sponsor
- Dispatch Biotherapeutics
- Start
- Apr 2026
- Primary completion
- Apr 2046
- Modality
- Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DV-10 and idecabtagene vicleucel in colorectal cancer (CRC), gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and 2 more, sponsored by Dispatch Biotherapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 2 years, Incidence of Dose Limiting Toxicities at 28 days and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
DV-10idecabtagene vicleucel
03
Conditions
colorectal cancer (CRC)gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal adenocarcinomabiliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07544589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544589.